Search results for "outcomes"

showing 10 items of 446 documents

Recovery from sauna bathing favorably modulates cardiac autonomic nervous system

2019

Objective: Sauna bathing is becoming a common activity in many countries and it has been linked to favorable health outcomes. However, there is limited data on the heart rate (HR) and heart rate variability (HRV) responses to an acute sauna exposure. Design: We conducted a single-group, longitudinal study utilizing a pre-post design to examine acute effects of sauna bathing on the autonomic nervous system as reflected by HRV. A total of 93 participants (mean [SD] age: 52.0 [8.8] years, 53.8% males) with cardiovascular risk factors were exposed to a single sauna session (duration: 30 min; temperature: 73 °C; humidity: 10–20%) and data on HRV variables were collected before, during and after …

MaleComplementary and Manual TherapyAcute effectssykemedicine.medical_specialtyLongitudinal studysaunominenCardiovascular risk factorsAutonomic Nervous SystemHealth outcomesSteam Bath03 medical and health sciencesSauna bathinglämpöhoito0302 clinical medicineHeart RateInternal medicineautonominen hermostoHeart ratemedicineHumansHeart rate variabilityLongitudinal Studies030212 general & internal medicineHeart rate variabilityCardiovascular responseAdvanced and Specialized Nursingbusiness.industryMiddle AgedHeat therapySauna bathingAutonomic nervous systemComplementary and alternative medicineCardiovascular DiseasesCardiologyFemalebusiness030217 neurology & neurosurgery
researchProduct

Absolok® versus Hem-o-Lok® clips for renorrhaphy during partial nephrectomy for parenchymal renal tumors

2020

Background To compare perioperative and functional outcomes associated with renorrhaphy performed with two different types of clips (Absolok® vs. Hem-o-Lok®) in a contemporary series of patients who underwent partial nephrectomy. Methods Patients in whom Absolok® clips were used to perform haemostasis at the level of tumor bed or to block the running sutures during sliding-clip renorrhaphy (study group) were compared with a contemporary control group of patients in whom renorrhaphy was performed with Hem-o-Lok® clips. Both groups received the same surgical technique via an open or robot-assisted approach. Inner renorrhaphy was performed with one or more 3-0 (26 mm needle) monofilament runni…

MaleComplicationsmedicine.medical_treatment030232 urology & nephrologyKidneyNephrectomyPolydioxanonechemistry.chemical_compoundPostoperative Complications0302 clinical medicinePerioperative outcomesRobotic Surgical ProceduresSuture (anatomy)bsolok® clipPartial nephrectomyMedicineProspective StudiesCLIPSIntraoperative ComplicationsProspective cohort studycomputer.programming_languageMiddle AgedSurgical InstrumentsMagnetic Resonance ImagingRenal cell carcinomaKidney NeoplasmsNephrectomyTreatment Outcomesurgical procedures operativeNephrologyPolydioxanone030220 oncology & carcinogenesiscardiovascular systemFemalePositive Surgical MarginAbsolok (R) clips Hem-o-lok (R) clips Renorrhaphy Sliding clip technique Partial nephrectomy Perioperative outcomes Complications Renal cell carcinomaPerioperative outcomeHem-o-Lok® clipmedicine.medical_specialtyKidney CortexUrologyeducationSliding clip technique03 medical and health sciencesHumansRenorrhaphycardiovascular diseasesAgedHemostasisAbsolok (R) clipsSuturesbusiness.industryPerioperativeSurgeryHem-o-lok (R) clipschemistryHemostasisTomography X-Ray ComputedbusinessComplicationcomputerMinerva Urologica e Nefrologica
researchProduct

Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?

2021

[Objective] The full phenotypic expression of non-alcoholic fatty liver disease (NAFLD) in lean subjects is incompletely characterised. We aimed to investigate prevalence, characteristics and long-term prognosis of Caucasian lean subjects with NAFLD.

MaleDiseaseBody Mass IndexCohort StudiesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseAdult Body Mass Index Cohort Studies Fatty liver Female Humans Male Middle Aged Non-alcoholic Fatty Liver Disease Non-alcoholic steatohepatitis Prognosis Survival Rate Thinness Whitesnonalcoholic steatohepatitis2. Zero hunger0303 health sciencesFatty liverNASHGastroenterologyMiddle AgedPrognosis3. Good healthSurvival RateCohort030211 gastroenterology & hepatologyFemalemedicine.symptomAdultmedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAdigestive systemWhite People03 medical and health sciencesThinnessNAFLDInternal medicinemedicineHumansPNPLA3030304 developmental biologyfatty liverbusiness.industryWhitesSettore MED/09 - MEDICINA INTERNAnutritional and metabolic diseasesmedicine.diseaseLean-NASHObesitydigestive system diseasesLean-OutcomesSteatohepatitisbusinessWeight gainBody mass index
researchProduct

Spectrum of congenital anomalies in pregnancies with pregestational diabetes

2012

BACKGROUND Maternal pregestational diabetes is a well-known risk factor for congenital anomalies. This study analyses the spectrum of congenital anomalies associated with maternal diabetes using data from a large European database for the population-based surveillance of congenital anomalies. METHODS: Data from 18 population-based EUROCAT registries of congenital anomalies in 1990-2005. All malformed cases occurring to mothers with pregestational diabetes (diabetes cases) were compared to all malformed cases in the same registry areas to mothers without diabetes (non-diabetes cases). RESULTS: There were 669 diabetes cases and 92,976 non diabetes cases. Odds ratios in diabetes pregnancies re…

MaleEmbryologyPediatricsPregestational DiabetesPregnancy in DiabeticsMELLITUSPregnancyRisk FactorsNeural Tube DefectsRegistriesLivebirthsRISKeducation.field_of_studyOUTCOMESlivebirthsWOMENEarGeneral MedicineASSOCIATIONCongenital AnomaliesEuropeAnotiaPopulation SurveillanceFemaleNEURAL-TUBE DEFECTSLive BirthHernia UmbilicalAdultHeart Defects Congenitalmedicine.medical_specialtyPopulationPopulation Basedpopulation basedCongenital AbnormalitiesYoung AdultDiabetes mellitusAnencephalyBIRTH-DEFECTSmedicineDiabetes MellitusHumansMALFORMATIONSRisk factoreducationTYPE-1Congenital MicrotiaOmphaloceleSpina bifidabusiness.industrycongenital anomaliesInfant NewbornOdds ratioNATIONWIDEmedicine.diseaseEstados de Saúde e de Doençapregestational diabetesPregnancy ComplicationsPediatrics Perinatology and Child HealthbusinessDevelopmental BiologyBirth Defects Research. Part A: Clinical and Molecular Teratology
researchProduct

Liraglutide and cardiovascular outcomes in type 2 diabetes

2016

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the hazard ratio. No adjus…

MaleGastrointestinal DiseasesTreatment outcomeClinical BiochemistryMyocardial InfarctionType 2 diabetes030204 cardiovascular system & hematologylaw.inventionMedicine; Endocrinology0302 clinical medicineRandomized controlled trialAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome; Medicine (all)lawCardiovascular DiseaseClinical-trial; Pancreatitis; Therapies; Cancer; Drugs11 Medical and Health SciencesResearch Support Non-U.S. Gov'tMedicine (all)PANCREATITISHazard ratioLEADER Steering CommitteeFollow up studiesGeneral MedicineMiddle AgedAlbiglutideMulticenter StudyStrokeTRIALSTreatment OutcomeCardiovascular DiseasesRandomized Controlled TrialFemaleLife Sciences & BiomedicineCardiovascular outcomesmedicine.drugHumanmedicine.medical_specialtyGastrointestinal DiseaseMEDLINE030209 endocrinology & metabolismLEADER Trial InvestigatorsPlaceboFollow-Up Studie03 medical and health sciencesMedicine General & InternalResearch Support N.I.H. ExtramuralDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicinemedicineJournal ArticleHumansHypoglycemic AgentsAgedGlycemic efficacyScience & TechnologyHypoglycemic AgentLiraglutidebusiness.industrySemaglutideLiraglutidemedicine.diseaseSurgeryDiabetes Mellitus Type 2businessFollow-Up Studies
researchProduct

PanCareLIFE

2018

Aims: Survival after cancer diagnosed during childhood or adolescence continues to improve with new treatments and supportive therapies. Optimal long-term care requires that risks to vulnerable organs are clearly defined and translated into guidelines that are implemented into practice. PanCareLIFE is a pan-European consortium that addresses survivorship issues comprising fertility, hearing impairment and quality of life. This article describes the scientific basis of PanCareLIFE's studies.Methods: PanCareLIFE involves 17 partner institutions from eight European countries, with additional 11 data providers from five other countries. Study designs and methods include molecular genetic, cohor…

MaleGerontologyCancer ResearchLongitudinal studyMedizinPilot ProjectsChildhood cancer survivors0302 clinical medicineNeoplasmsLYMPHOMAMedicineFertility preservationChild610 Medicine & healthEARLY MENOPAUSEOVARIAN-FUNCTIONmedia_commonSURVIVORSOUTCOMES030219 obstetrics & reproductive medicineFertility PreservationGENETIC-VARIATIONCHEMOTHERAPYEuropeOncologyChild Preschool030220 oncology & carcinogenesisCohortFemalemedicine.symptom360 Social problems & social servicesAdultQuality of lifeAdolescentHearing lossmedia_common.quotation_subjectFertilityGuidelinesYoung Adult03 medical and health sciencesQuality of life (healthcare)SDG 3 - Good Health and Well-beingHumansCHILDHOOD-CANCERbusiness.industryClinical study designLate effectsHEARING-LOSSInfant NewbornInfantOtotoxicityLong-Term CareGonadal impairmentLong-term careFeasibility StudiesbusinessFOLLOW-UPEuropean Journal of Cancer
researchProduct

Occupational Exposure to Endocrine-Disrupting Chemicals and Birth Weight and Length of Gestation: A European Meta-Analysis

2016

BACKGROUND: Women of reproductive age can be exposed to endocrine-disrupting chemicals (EDCs) at work, and exposure to EDCs in pregnancy may affect fetal growth. OBJECTIVES: We assessed whether maternal occupational exposure to EDCs during pregnancy as classified by application of a job exposure matrix was associated with birth weight, term low birth weight (LBW), length of gestation, and preterm delivery. METHODS: Using individual participant data from 133,957 mother-child pairs in 13 European cohorts spanning births from 1994 through 2011, we linked maternal job titles with exposure to 10 EDC groups as assessed through a job exposure matrix. For each group, we combined the two levels of e…

MaleGerontologyEmbaràs -- ComplicacionsHealth Toxicology and Mutagenesisprenatal exposurePublic Health Environmental and Occupational Health; Health Toxicology and MutagenesisEndocrine Disruptors010501 environmental sciencesoutcomes01 natural sciencesDones embarassades -- Treball0302 clinical medicineEndocrinologyEndocrinologiaPregnancyBirth Weight030212 general & internal medicinepolycyclic aromatic-hydrocarbonsObstetricsGestational age3. Good healthEuropeHealthMaternal ExposureGestationFemaleGeneration RPublic Healthpregnancymedicine.symptompreterm deliverymedicine.medical_specialtyfetal-growthBirth weightJob-exposure matrixGestational Age03 medical and health sciencesEmbarassadesOccupational ExposuremedicineHumansToxicology and Mutagenesisair-pollution0105 earth and related environmental sciences[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/HealthPregnancybusiness.industryResearchPregnant womenEnvironmental and Occupational HealthInfant NewbornPublic Health Environmental and Occupational HealthOdds ratioInfant Low Birth Weightmedicine.diseaseLow birth weightbisphenol-ahealth researchContaminació -- Aspectes ambientalsgeneration rbusiness
researchProduct

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countrie…

2015

Summary Background Up-to-date evidence about levels and trends in disease and injury incidence, prevalence, and years lived with disability (YLDs) is an essential input into global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013), we estimated these quantities for acute and chronic diseases and injuries for 188 countries between 1990 and 2013. Methods Estimates were calculated for disease and injury incidence, prevalence, and YLDs using GBD 2010 methods with some important refinements. Results for incidence of acute disorders and prevalence of chronic disorders are new additions to the analysis. Key improvements include expansion to the cause an…

MaleGerontologyNutrition and DiseaseEpidemiologyyears lived with disability Global burden of disease acute and chronic diseases countriesPrevalenceDiseaseGlobal HealthMedical and Health SciencesConduct disorderOtitis-mediaCost of IllnessResidence CharacteristicsVoeding en ZiekteEpidemiologyPrevalence80 and overGlobal health2.2 Factors relating to the physical environment2.1 Biological and endogenous factorscountriesAetiologyChildAged 80 and overMedicine(all)education.field_of_studyATTENTION-DEFICIT/HYPERACTIVITY DISORDERIncidenceMortality rateIncidence (epidemiology)Pain ResearchNeglected DiseasesAlcohol dependenceGeneral MedicineMiddle AgedGlobal burden of diseaseGlobal Burden of Disease Study 2013 CollaboratorsMental HealthInfectious DiseasesAttention deficit/Hyperactivity disorderBurden of IllnessChild PreschoolAcute DiseaseFemaleLife Sciences & BiomedicineAdultmedicine.medical_specialtyAdolescentGBD 2013Populationacute and chronic diseasesYoung AdultMental-disordersAge DistributionMedicine General & InternalWeightsGeneral & Internal MedicinemedicineHumansLife ScienceDisabled PersonsSex DistributionPreschooleducationDeveloping CountriesVLAGAgedScience & Technologybusiness.industryDeveloped CountriesCutaneous LeishmaniasisInfant NewbornInfantHealth outcomesNewbornmedicine.diseaseComorbidityBrain Disordersyears lived with disabilityGood Health and Well BeingDisease injury incidence prevalence YLDs GBD 2010Chronic DiseaseWounds and Injuriesbusiness2.4 Surveillance and distributionIron-deficiencyDemography
researchProduct

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

2018

It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TK…

MaleImatinib mesylate discontinuation; chronic myelogenous leukemia; treatment-free remission; long-term outcomes; molecular response; cml patients; recommendations; management; dasatinib; cessationchemistry.chemical_compound0302 clinical medicineTreatment Free RemissionPregnancyMED/15 - MALATTIE DEL SANGUEInterquartile rangeingleseMedicinedasatinibChronic Myelogenous Leukemiatreatment-free remissionPonatinibmolecular responseHematologyMiddle AgedProtein-Tyrosine Kinasescml patientsDasatinibTreatment OutcomeLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylateFemaleChronic Myelogenous Leukemia; Discontinuation; Treatment Free Remissionlong-term outcomesmanagementmedicine.drugAdultmedicine.medical_specialtyChronic Myeloid LeukemiaSocio-culturaleDiscontinuationArticletyrosine kinase inhibitors discontinued treatment chronic myeloid leukemia treatment-free remission (TFR)Safety-Based Drug Withdrawals03 medical and health scienceschronic myeloid leukemia tyrosine kinase inhibitors discontinuationMedian follow-upLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicineImatinib mesylate discontinuationHumansProtein Kinase InhibitorsRetrospective Studiesbusiness.industryImatinibmedicine.diseaseDiscontinuationrespiratory tract diseasesSettore MED/15 - MALATTIE DEL SANGUEcessationNilotinibchemistryrecommendationsbusiness030215 immunologyChronic myelogenous leukemia
researchProduct

Preconception genome medicine: current state and future perspectives to improve infertility diagnosis and reproductive and health outcomes based on i…

2021

Abstract BACKGROUND Our genetic code is now readable, writable and hackable. The recent escalation of genome-wide sequencing (GS) applications in population diagnostics will not only enable the assessment of risks of transmitting well-defined monogenic disorders at preconceptional stages (i.e. carrier screening), but also facilitate identification of multifactorial genetic predispositions to sub-lethal pathologies, including those affecting reproductive fitness. Through GS, the acquisition and curation of reproductive-related findings will warrant the expansion of genetic assessment to new areas of genomic prediction of reproductive phenotypes, pharmacogenomics and molecular embryology, fur…

MaleInfertilitymedicine.medical_specialtyPopulationReproductive medicineGenome-wide association studyBioinformaticspolygenic medicinegenetic diagnosis03 medical and health sciences0302 clinical medicinePregnancyreproductive geneticsOutcome Assessment Health CaremedicineGenetic predispositionHumanswhole-exome sequencingProspective StudieseducationIVF/ICSI outcomesExome sequencing030304 developmental biologyReproductive healthGenetic testing0303 health scienceseducation.field_of_study030219 obstetrics & reproductive medicinemedicine.diagnostic_testoocyte and embryo genetic defectsbusiness.industryObstetrics and GynecologyGenomicsmedicine.disease3. Good healthReproductive Medicinewhole-genome sequencingInfertilitygenomic sequencingpreconception carrier screeningFemaleinfertilitybusinessGenome-Wide Association StudyHuman Reproduction Update
researchProduct